Overview

Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma

Status:
Completed

Trial end date:
2021-04-01

Target enrollment:

Participant gender:

Summary

Children, adolescents and young adults with relapsed or treatment refractory pineoblastoma (rPB) represent a group of patients with dismal prognosis for whom a recommended standard salvage therapy is currently not available.

Phase:

Phase 2

Details

Lead Sponsor:

University of Regensburg

Treatments:

Dasatinib
Everolimus
Irinotecan
Protein Kinase Inhibitors
Sirolimus
Temozolomide
Titanium dioxide
Topoisomerase I Inhibitors